What is NuSirt Sciences?
NuSirt Sciences is a biotechnology firm dedicated to creating technologies that evaluate the impact of natural compounds and pharmaceuticals on chronic diseases associated with overnutrition and aging. The company's core research targets therapies for cardiometabolic conditions, including metabolic-associated fatty liver disease, obesity, type 2 diabetes, and hypertension. These therapeutic approaches have been validated through rigorous preclinical studies and clinical trials. NuSirt Sciences offers LEUSIX, a dietary supplement designed to support cardiometabolic health and weight management, alongside its development of TRIPLN, a combination therapy.
How much funding has NuSirt Sciences raised?
NuSirt Sciences has raised a total of $20.6M across 4 funding rounds:
Series B
$9.1M
Series A
$3.5M
Series C
$6M
Private Equity
$2M
Series B (2014): $9.1M, investors not publicly disclosed
Series A (2014): $3.5M led by Mountain Group Capital, Tennessee Community Ventures Fund, and William Guttman
Series C (2015): $6M supported by Mountain Group Partners, Hatteras Venture Partners, and TriStar Technology Ventures
Private Equity (2016): $2M, investors not publicly disclosed
Key Investors in NuSirt Sciences
Mountain Group Partners
Mountain Group Partners is a venture capital firm specializing in early-stage Life Sciences, AgTech, and Technology investments, known for its hands-on approach to shaping companies from inception.
Hatteras Venture Partners
Hatteras Venture Partners focuses on building transformative biotech, MedTech, and HealthTech companies, providing capital and strategic support to advance innovative healthcare solutions.
TriStar Technology Ventures
TriStar Technology Ventures operates within the Custom Software & IT Services industry, contributing to the technological infrastructure that supports companies like NuSirt Sciences.
What's next for NuSirt Sciences?
The recent major strategic investment in NuSirt Sciences positions the company for accelerated growth and the expansion of its therapeutic offerings. With a focus on addressing prevalent chronic diseases, the company is poised to leverage this capital to advance its TRIPLN combination therapy through further clinical development and to scale the market reach of its LEUSIX dietary supplement. This strategic financing is expected to bolster research and development efforts, potentially leading to new partnerships and a stronger market presence in the competitive biopharmaceutical landscape.
See full NuSirt Sciences company page
